Dai Ichi Life Insurance Company Ltd increased its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 22.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,987 shares of the biopharmaceutical company’s stock after buying an additional 3,717 shares during the quarter. Dai Ichi Life Insurance Company Ltd’s holdings in Alexion Pharmaceuticals were worth $2,432,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Morgan Stanley grew its holdings in Alexion Pharmaceuticals by 112.0% in the 1st quarter. Morgan Stanley now owns 585,482 shares of the biopharmaceutical company’s stock worth $70,983,000 after buying an additional 309,299 shares in the last quarter. Commerzbank Aktiengesellschaft FI grew its holdings in Alexion Pharmaceuticals by 151.5% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 132,698 shares of the biopharmaceutical company’s stock worth $16,145,000 after buying an additional 79,943 shares in the last quarter. Baird Financial Group Inc. grew its holdings in Alexion Pharmaceuticals by 219.0% in the 1st quarter. Baird Financial Group Inc. now owns 14,606 shares of the biopharmaceutical company’s stock worth $1,771,000 after buying an additional 10,028 shares in the last quarter. LMR Partners LLP bought a new position in Alexion Pharmaceuticals in the 1st quarter worth approximately $927,000. Finally, Fox Run Management L.L.C. bought a new position in Alexion Pharmaceuticals in the 2nd quarter worth approximately $426,000. 94.26% of the stock is owned by institutional investors and hedge funds.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 144.07 on Wednesday. The firm’s 50-day moving average is $137.20 and its 200 day moving average is $124.25. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $149.34. The firm has a market capitalization of $32.15 billion, a P/E ratio of 62.48 and a beta of 1.40.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.08 by $0.48. The business had revenue of $912.00 million for the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm’s revenue was up 21.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.13 EPS. Equities analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.61 EPS for the current year.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 700 shares of the business’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the sale, the director now directly owns 6,315 shares of the company’s stock, valued at approximately $869,828.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bros. Advisors Lp Baker purchased 660,779 shares of the business’s stock in a transaction on Thursday, June 15th. The shares were acquired at an average cost of $117.33 per share, for a total transaction of $77,529,200.07. The disclosure for this purchase can be found here. Insiders sold a total of 17,070 shares of company stock worth $2,416,869 over the last ninety days. 4.35% of the stock is currently owned by insiders.

ALXN has been the subject of a number of research reports. TheStreet raised Alexion Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Friday, July 14th. UBS AG reaffirmed a “buy” rating and set a $140.00 price target (down from $143.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 31st. Deutsche Bank AG decreased their price target on Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating for the company in a research note on Thursday, May 25th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $158.00 price target on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $157.00 price target on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Five equities research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and three have assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $157.09.

TRADEMARK VIOLATION WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) Position Boosted by Dai Ichi Life Insurance Company Ltd” was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/09/13/alexion-pharmaceuticals-inc-alxn-position-boosted-by-dai-ichi-life-insurance-company-ltd.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.